EMA Eyes Second Half Of 2016 For Public Hearings On Marketed Medicines
This article was originally published in SRA
Executive Summary
The European Medicines Agency's pharmacovigilance committee, PRAC, could be ready to start holding public hearings to support the safety review of certain medicines on the market by the second half of this year. The hearings, when in place, will open up the EU's drug assessment process to the public for the first time.